In-licensing opportunity assessment

A clinical-stage biotech needed near-term value inflection beyond its lead asset and a defensible short-list to put in front of its board.

X981-175

Emerging science reviewed across candidates

Situation

Late-stage portfolio growth

Late clinical stage biotech seeking to grow company pipeline with a commercial launch projected for the following year.
Client had promising early-stage in-house portfolio with longer-term horizon, but sought opportunities with potential for near-term value inflection beyond lead asset.
Client has a limited BD team, so needed a consulting partner to help with rapid prioritization of potential in-licensing opportunities and deeper analysis for assets of higher interest.

Project

Opportunity triage and deep dive

Developed bespoke framework for identifying potential assets that aligned with company priorities, scientific/clinical adjacencies and potential commercial footprint.
Screened 50+ opportunities sourced from company and investment banks; filtering by scientific, clinical and commercial dimensions to prioritize ~10 for deeper analysis.
Conducted detailed assessments included KOL interviews and secondary research with focus on strength of biologic rationale, time/cost to POC data, market potential given standard-of-care and competitive pipeline.

Standardized scorecard used to triage opportunities

Asset deep-dives supported recommendations

Outcome

Recommended assets

Process identified two assets that were most attractive following initial screen and deep-dives.
Presented findings to Board of Directors with recommendation to proceed to diligence and potential acquisition discussions.
Board provided go-ahead and company moved forward with BD activities.

MORE CASE STUDIES

Related work

Institutional

Strategy for Statewide Health Information Exchange

A non-profit health information exchange was facing financial struggles and needed a new strategy that would keep it financially sustainable

HIE, Health IT,

Medtech, Early Stage

Growth strategy for point-of-care testing

Post pandemic an innovative diagnostics platform company wanted to dramatically increase its market by targeting retail clinics for its point-of-care diagnostics platform

Growth, product market fit, value proposition

Institutional

University Trials

Large university wanting to dramatically increase its clinical research footprint